Legend Biotech is a global, clinical-stage biotechnology company developing and manufacturing novel therapies. We explore and apply innovative technologies to deliver safe, efficacious and cutting-edge options for patients around the world.
We came together as a team of experts, committed to quality, driven by excellence, and dedicated to experimentation. Though we faced many challenges, we remained fearless in our research and rigorous in our thinking, as we push ourselves to work harder.
What keeps us moving is the enormous burden patients bear and the difficulties they face.
We believe it’s time to accelerate and expand that transformation. At Legend Biotech, we are excited to bring clinical trials to patients in our pursuit of a cure. While we are focused on CAR-T in multiple myeloma, we firmly believe the prospects of cellular therapy stretch beyond just one disease or indication.
The spark of hope is lit. At Legend Biotech, we're using that hope to ignite the future of CAR-T cell therapy.
We came together as a team of experts, committed to quality, driven by excellence, and dedicated to experimentation. Though we faced many challenges, we remained fearless in our research and rigorous in our thinking, as we push ourselves to work harder.
What keeps us moving is the enormous burden patients bear and the difficulties they face.
We believe it’s time to accelerate and expand that transformation. At Legend Biotech, we are excited to bring clinical trials to patients in our pursuit of a cure. While we are focused on CAR-T in multiple myeloma, we firmly believe the prospects of cellular therapy stretch beyond just one disease or indication.
The spark of hope is lit. At Legend Biotech, we're using that hope to ignite the future of CAR-T cell therapy.
Location: United States, New Jersey
Employees: 501-1000
Total raised: $150.5M
Founded date: 2014
Investors 3
| Date | Name | Website |
| - | LAV | lavfund.co... |
| - | RA Capital... | racap.com |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.04.2020 | Series A | $150.5M | - |
Mentions in press and media 20
| Date | Title | Description |
| 25.10.2024 | Innovations in Drug Delivery: A Leap Towards the Future | In the ever-evolving landscape of healthcare, innovation is the lifeblood that keeps the industry vibrant. Recently, two significant events showcased groundbreaking advancements in drug delivery and biopharmaceuticals. The PDA Universe of P... |
| 24.10.2024 | Global Biopharma Thought Leaders Gather in London: Join the 2024 GenScript Biotech Global Forum for Cutting-Edge Insights | PISCATAWAY, N.J., Oct. 24, 2024 /PRNewswire/ -- Cell therapy, gene therapy, and mRNA vaccines are revolutionizing healthcare, offering innovative treatments for a wide range of diseases. However, as these therapies progress, they encounter ... |
| 30.09.2024 | The Rising Tide of Chinese Biopharmaceuticals: A Global Perspective | The biopharmaceutical landscape is shifting. Chinese companies are no longer just local players; they are emerging as global contenders. The recent collaboration between Anbogen and BeiGene exemplifies this trend. Anbogen, a clinical-stage ... |
| 28.09.2024 | Frost & Sullivan Released Report: "2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends" | SHANGHAI, Sept. 28, 2024 /PRNewswire/ -- Frost & Sullivan released the "2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends" which focus on the progress of Chinese biopharmaceuticals going glob... |
| 15.09.2024 | Dialogue with CGT Leaders! You Are Invited to Join the "2024 GenScript Biotech Global Forum•London" to Discuss the Future Together | PISCATAWAY, N.J., Sept. 15, 2024 /PRNewswire/ -- The year 2024 marks a milestone year for continuous advancements in Cell and Gene Therapy (CGT). The global launch of Amtagvi, a Tumor-Infiltrating Lymphocyte (TIL) therapy, has ushered in a ... |
| 27.08.2024 | GenScript Subsidiary Legend Biotech Achieves Breakthrough with Cilta-cel Approval in China, Offering New Hope for Multiple Myeloma Patients | PISCATAWAY, N.J., Aug. 27, 2024 /PRNewswire/ -- Legend Biotech (NASDAQ: LEGN), a subsidiary of GenScript Biotech Corporation (hereinafter referred to as "GenScript"), a global leader in life sciences research and manufacturing ser... |
| 01.06.2024 | Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse | BOSTON, June 1, 2024 /PRNewswire/ -- Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca® mouse. The IGH-VDJ genes in the mouse genome have been successfully replaced by... |
| 01.06.2024 | Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse | BOSTON, June 1, 2024 /PRNewswire/ -- Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca® mouse. The IGH-VDJ genes in the mouse genome have been successfully replaced by... |
| 11.03.2024 | Next-gen leaders: The biotech stock set to soar on groundbreaking innovation | The biotech industry is evolving rapidly, with 2024 poised to be a year of significant advancements and opportunities. Amidst an uncertain macroeconomic environment, the biotech sector is gaining momentum, fueled by groundbreaking innovatio... |
| 14.11.2023 | Legend Biotech’s deal with Novartis is a reminder that biotech’s bear market has a few haves, and many have-nots | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with the latest twist in the Ozempic panic, polarizing data in genome editing, and anot... |
Show more